Aurobindo Pharma gets final USFDA nod for gastro reflux drug

Posted by: Corporate Communications / VIVAN Life Sciences March 31, 2016

Aurobindo Pharma gets final USFDA nod for gastro reflux drug

NEW DELHI: Drug firm Aurobindo PharmaBSE -0.64 % has received final approval from the USFDA to manufacture and market pantoprazole sodium for injections, used for the treatment of gastroesophageal reflux disease, in the American market.

“The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market pantoprazole sodium for injections, 40 mg/vial,” Aurobindo Pharma said in a BSE filing.

The firm said this product is expected ..

Read more at:
http://economictimes.indiatimes.com/articleshow/51629071.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst